Article

A Genetic Model for Central Chondrosarcoma Evolution Correlates with Patient Outcome

2021-11-08

Abstract excerpt

The treatment options for central chondrosarcoma are limited, and prognoses are generally unreliable. The presence and absence of mutations in IDH1 , and IDH2 are defining events, and TERT mutations have been recently been associated with poor outcome. Despite this, molecular biomarkers are lacking. Here, analysing data from 356 patients, comprising results from whole genome sequencing (n=68), digital droplet PCR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 16558333-e8cf-5e77-aa12-02fd427a9537
DOI: 10.1101/2021.11.02.21265785

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Genetic Model for Central Chondrosarcoma Evolution Correlates with Patient OutcomeDOI 10.1101/2021.11.02.21265785Read

A genetic model for central chondrosarcoma evolution correlates with patient outcome.Semantic proximity Read

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.Semantic proximity Read

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade ChondrosarcomaSemantic proximity Read

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.Semantic proximity Read

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic TargetsSemantic proximity Read

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaSemantic proximity Read

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.Semantic proximity Read

TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.Semantic proximity Read

Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.Semantic proximity Read

IDH Mutations in Chondrosarcoma: Case Closed or Not?Semantic proximity Read